ENOblock treatment inhibited gluconeogenesis, adiposity and obesity-related inflammation via concomitant repression of the regulatory genes Pck-1, Srebp-1a and Srebp-1c, and Tnf-a and Il-6. This evidence concerns the gene PCK1 and Obesity.